Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. The scenarios in ...

Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.

The researchers found that the 5-year risks for revision among 3691 participants was 5.6% for patients in the weight gain or stable weight group compared with 3.9% in patient with greater than 10% ...

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...